The transmissible venereal tumor (TVT) is a contagious neoplasm of round cells that frequently affect dogs. The treatment consists of chemotherapy being more effective the vincristine alone, however the resistance emergence to this agent due multidrug resistance of the P-glycoprotein (P-gp), a transporter protein encoded by the MDR1 gene, has been taking the association with other drugs. Recent studies demonstrated the antitumoral effect of the avermectins when associated to the vincristine in the treatment of some neoplasms. Therefore, the objective of the present study was to compare the effectiveness of standard treatment of TVT with vincristine only when compared to combined treatment with vincristine and ivermectin, evaluated through number of applications of the two protocols, histopathological and cytological analysis from 50 dogs diagnosed with TVT during the period of 2007 to 2010. The combined protocol significant reduced the number of applications and cytological and histopathological findings collaborate with the hypothesis that the combination of vincristine and ivermectin promotes faster healing than the use of vincristine alone. Combination treatment with vincristine and ivermectin could be in the future an excellent therapeutic alternative for the treatment of TVT for probably reducing the resistance to vincristine, simultaneously reducing the cost of TVT treatment and promoting a faster recovery of the dog. Keywords: transmissible venereal tumor; ivermectin; vincristine; cytology; histopathology.
INTRODUCTION

The transmissible venereal tumor (TVT)
is a naturally occurring round cell neoplasm that affects dogs in tropical and subtropical countries (MACEWEN, 1996) . TVT is located mainly in the mucosa of the external genitalia of both sexes, but there are reports of cases in oral and nasal cavities, eyes, skin, tonsils, liver, pharynx, spleen, kidneys, brain, ovary, and foreskin, as well as the anal and perianal region (ROGERS et al., 1998; DAS; DAS, 2000) .
The methods used to treat TVT are cryosurgery, radiotherapy, surgical resection and antineoplastic chemotherapy that is the protocol of choice in routine clinical treatment (NAK et al., 2005) . Antineoplastic treatment may combine two or more chemotherapeutic agents (for example, vincristine and cyclophosphamide combined with methotrexate), or it can involve a single agent as vincristine (in which case is most effective or doxorubicin) (MACEWEN, 1996; NAK et al., 2005) . However, the extensive use of vincristine in recent years resulted in the emergence of TVT resistance to the drug in Brazil with more applications than described in the literature (on average of four to six applications) (SILVA et al., 2007; GASPAR et al., 2009) . Furthermore, some TVT may not respond to multiple administrations of chemotherapy (HARMELIN et al., 1995) .
It is known that the main factor responsible for the emergence of multidrug resistance is the P-glycoprotein (P-gp), a transporter protein encoded by the MDR1 gene that exists in normal tissues (CNS, intestinal cells, renal tubular cells and bile canaliculi) and tumor tissues. The P-gp is a substrate for various molecules, including for the antineoplastic drug vincristine (KORYSTOV et al., 2004) and other drugs such as vinblastine, doxorubicin, avermectins and loperamide (MEALEY et al., 2003) . The mechanism of action of P-gp is not yet fully elucidated, but it is known that it is involved in the efflux of substances from within the cell, as an important drug efflux pump that is expressed on the membranes of blood-brain barrier (BBB) for example, thus allowing these to be excreted rather than absorbed by the body (DOWLING, 2006) . Neurotoxicity is observed in Collies when ivermectin is administered in therapeutic dosages, due to a mutation in the MDR1 gene (DOWLING, 2006; MEALEY et al., 2002; HOPPER et al., 2002) .
Recently, a study showed the antitumor effect of ivermectin in the treatment of some cancers in rats (DRINYAEV et al., 2004) and another study demonstrated the synergistic effect of a combination of avermectin and vincristine that may increase the antitumor effect of the antineoplastic agent and reduce resistance to vincristine, which has become increasingly common in recent years (KORYSTOV et al., 2004) . Ivermectin, besides abamectin and selamectin, inhibits the P-gp dependent drug resistance profiles tumors cells and also is a potent substrate and inhibitor for P-gp in Caco-2 cells (POULIOT et al., 1997; DIDIER; LOOR, 1996; GRIFFIN et al., 2005) .
Another study (ANDRADE et al., 2009) found that a combination of vincristine and ivermectin was more effective than treatment with vincristine alone, for the treatment of TVT. They reported that the former protocol required a decreased number of applications, in spite of not being statically significant, with no changes to physical or haematological analyses.
Therefore, this study aimed to verify the efficacy of the combination of vincristine and ivermectin and compare it with the isolated use of vincristine in the treatment of TVT, assessing the progress of healing through cytological and histopathological analyses of the tumor. 
MATERIAL AND METHODS
Experimental design
Statistical analysis
The mean values of the number of administrations of the protocol treatment in VG and VIG, from dogs diagnosed with TVT were compared and analyzed by Student t-tests. A significance level of P < 0.05 was adopted. For assessment of microscopic variables, we adopted the "neoplastic infiltration in dermis" criterion in biopsies samples for independent observations in both groups. We used the binomial test for two proportions and BioEstat 5.0 statistical software, with a significance level of 5%. The sample size was sufficient to approximate binomial distribution to the normal curve.
RESULTS AND DISCUSSION
The number of administrations with VIG protocol was significantly reduced (P < 0.05) than VG protocol. In the VG protocol the numbers of administrations were 5.5±1.8 (range 4-9) while in VIG protocol was 3.2±1.8 (range 2-8). The criteria neoplastic infiltration in dermis was significant difference in both protocols. The VIG group showed earlier a significantly reduced (P < 0.05) than VG protocol in histopathological samples. It 
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